Latest News

• 26 May 2022 – Destiny Pharma plc Board changes
• 12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe
• 04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role
• 03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer
• 27 April 2022 – Posting of Annual Report and Notice of AGM
• 12 April 2022 – Audited results for year ended 31 December 2021
• 31 March 2022 – Presenting data at the ECCMID 2022 Congress
• 28 March 2022 – Result of General Meeting and Total Voting Rights
• 25 March 2022 – Result of Open Offer
• 25 March 2022 – Destiny’s microbiome project article published in Vantage
• 23 March 2022 – Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon”
• 22 March 2022 – Exercise of Options and Total Voting Rights
• 17 March 2022 – Open Offer Application Form
• 17 March 2022 – Form of Proxy
• 09 March 2022 – Circular to shareholders
• 08 March 2022 – Fundraising
• 08 February 2022 – Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme
• 01 February 2022 – Positive data in XF-73 Dermal study with NIAID
• 24 January 2022 – Clinical and commercial opportunity of NTCD-M3
• 21 January 2022 – Destiny Pharma Lancet Report
• 17 January 2022 – Strategy/Company/Ops Update